Atossa Genetics Inc (ATOS)

Currency in USD
5.2800
-0.0500(-0.94%)
Real-time Data·
ATOS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.21005.5400
52 wk Range
4.905019.3500
Key Statistics
Prev. Close
5.33
Open
5.33
Day's Range
5.21-5.54
52 wk Range
4.905-19.35
Volume
46.59K
Average Volume (3m)
115.64K
1-Year Change
-56.2733%
Book Value / Share
5.78
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATOS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
80.0000
Upside
+1,415.15%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Atossa Genetics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Atossa Genetics Inc Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Atossa Genetics Inc Earnings Call Summary for Q4/2024

  • Atossa Genetics Q4 2024 EPS of -0.04 beats -0.065 forecast; stock up 0.47% to $0.752
  • Net loss reduced to $25.5M from $30.1M in 2023; operating expenses down to $27.6M from $31.4M
  • Cash position strong at $71.1M; company prioritizing Zendoxifen development for breast cancer
  • FDA consultations expected in 4-6 months; U.S. market focus with global expansion planned for 2026
  • Analyst price targets range $4-$7; company maintains "Fair" financial health score of 2.45/5
Last Updated: 2025-03-25, 10:10 a/m
Read Full Transcript

Compare ATOS to Peers and Sector

Metrics to compare
ATOS
Peers
Sector
Relationship
P/E Ratio
−1.6x−2.0x−0.5x
PEG Ratio
0.160.010.00
Price/Book
0.9x2.0x2.6x
Price / LTM Sales
-8.5x3.3x
Upside (Analyst Target)
-225.0%48.1%
Fair Value Upside
Unlock17.2%7.7%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 80.0000
(+1,415.15% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Craig-Hallum
Buy35.00+562.88%60.00MaintainFeb 04, 2026
Ascendiant Capital
Buy8.00+51.52%7.75MaintainDec 08, 2025
H.C. Wainwright
Buy7.00+32.58%-MaintainDec 05, 2025
H.C. Wainwright
Buy7.00+32.58%-MaintainOct 07, 2025
H.C. Wainwright
Buy7.00+32.58%-MaintainSep 09, 2025

Earnings

Latest Release
Nov 12, 2025
EPS / Forecast
-0.07 / -0.06
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ATOS Income Statement

People Also Watch

4.280
APPS
+1.06%
3.594
SLS
+1.80%
4.94
ALT
+0.41%
0.05
IRBTQ
-66.97%
16.588
REP
+2.71%

FAQ

What Is the Atossa Genetics (ATOS) Stock Price Today?

The Atossa Genetics stock price today is 5.2800

What Stock Exchange Does Atossa Genetics Trade On?

Atossa Genetics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Atossa Genetics?

The stock symbol for Atossa Genetics is "ATOS."

What Is the Atossa Genetics Market Cap?

As of today, Atossa Genetics market cap is 45.64M.

What Is Atossa Genetics's Earnings Per Share (TTM)?

The Atossa Genetics EPS (TTM) is -3.52.

When Is the Next Atossa Genetics Earnings Date?

Atossa Genetics will release its next earnings report on Apr 01, 2026.

From a Technical Analysis Perspective, Is ATOS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Atossa Genetics Stock Split?

Atossa Genetics has split 3 times.

How Many Employees Does Atossa Genetics Have?

Atossa Genetics has 15 employees.

What is the current trading status of Atossa Genetics (ATOS)?

As of Feb 06, 2026, Atossa Genetics (ATOS) is trading at a price of 5.2800, with a previous close of 5.3300. The stock has fluctuated within a day range of 5.2100 to 5.5400, while its 52-week range spans from 4.9050 to 19.3500.

What Is Atossa Genetics (ATOS) Price Target According to Analysts?

The average 12-month price target for Atossa Genetics is USD80.0000, with a high estimate of USD119.99994 and a low estimate of USD35. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1,415.15% Upside potential.

What Is the ATOS Premarket Price?

ATOS's last pre-market stock price is 5.5300. The pre-market share volume is 290.0000, and the stock has decreased by 0.2000, or 3.7500%.

What Is the ATOS After Hours Price?

ATOS's last after hours stock price is 5.5500, the stock has decreased by 0.2200, or 4.1300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.